Cargando…

Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)

BACKGROURD: H. pylori-associated gastric cancer is the first cancer-related death in Bhutan. Effective regimen for H. pylori eradication is essential to reduce risk of developing gastric cancer. Clarithromycin is not widely used in this limited resource country. Aim of this study was to evaluate pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilaichone, Ratha-Korn, Aumpan, Natsuda, Ratanachu-ek, Thawee, Gumnarai, Pornpen, Uchid, Tomohisa, Tshering, Lotay, Mahachai, Varocha, Yamaoka, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445957/
https://www.ncbi.nlm.nih.gov/pubmed/32334478
http://dx.doi.org/10.31557/APJCP.2020.21.4.1109
_version_ 1783574086275825664
author Vilaichone, Ratha-Korn
Aumpan, Natsuda
Ratanachu-ek, Thawee
Gumnarai, Pornpen
Uchid, Tomohisa
Tshering, Lotay
Mahachai, Varocha
Yamaoka, Yoshio
author_facet Vilaichone, Ratha-Korn
Aumpan, Natsuda
Ratanachu-ek, Thawee
Gumnarai, Pornpen
Uchid, Tomohisa
Tshering, Lotay
Mahachai, Varocha
Yamaoka, Yoshio
author_sort Vilaichone, Ratha-Korn
collection PubMed
description BACKGROURD: H. pylori-associated gastric cancer is the first cancer-related death in Bhutan. Effective regimen for H. pylori eradication is essential to reduce risk of developing gastric cancer. Clarithromycin is not widely used in this limited resource country. Aim of this study was to evaluate proper regimen and prevalence of antibiotic resistance pattern for H. pylori eradication in Bhutan. METHODS: Five hundred and forty-six patients underwent gastroscopy during GASTROCAMP between October 2014 and April 2015 in Bhutan and 77 patients were enrolled. Four gastric biopsies were obtained for rapid urease test, histopathology, H. pylori culture with Epsilometer test. All H. pylori-positive patients were randomized to receive either 7-day or 14-day of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily. RESULTS: Seventy-seven subjects were enrolled (54 females, 23 males, mean age = 45.4 years). Of 77 patients, 52 (67.5%) received 7-day regimen while 25 (32.5%) had 14-day regimen. Prevalence of H. pylori was 38.2%. Antibiotic resistance was 80.0% for metronidazole, 11.1% for levofloxacin and no resistance seen in amoxicillin, tetracycline and clarithromycin. Overall eradication rates of 7-day and 14-day regimens were 51.9% and 80.0%, p = 0.02. Female and age ≥40 years had significantly higher eradication rate when receiving 14-day compared to 7-day regimen (94.1% vs. 45.9%, OR = 18.82; 95% CI 2.26-157.02, p = 0.0007 and 86.7% vs. 50.0%, OR = 6.50; 95% CI 1.25-33.91, p = 0.02, respectively). CONCLUSIONS: Fourteen-day regimen might be an acceptable regimen for H. pylori eradication in limited resource area such as Bhutan. Female and age ≥40 years should receive longer duration of treatment. This 14-day regimen could at least reduce the risk of developing H. pylori-associated diseases especially peptic ulcer with complications and gastric cancer which lead to many deaths in Bhutan.
format Online
Article
Text
id pubmed-7445957
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-74459572020-09-02 Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) Vilaichone, Ratha-Korn Aumpan, Natsuda Ratanachu-ek, Thawee Gumnarai, Pornpen Uchid, Tomohisa Tshering, Lotay Mahachai, Varocha Yamaoka, Yoshio Asian Pac J Cancer Prev Research Article BACKGROURD: H. pylori-associated gastric cancer is the first cancer-related death in Bhutan. Effective regimen for H. pylori eradication is essential to reduce risk of developing gastric cancer. Clarithromycin is not widely used in this limited resource country. Aim of this study was to evaluate proper regimen and prevalence of antibiotic resistance pattern for H. pylori eradication in Bhutan. METHODS: Five hundred and forty-six patients underwent gastroscopy during GASTROCAMP between October 2014 and April 2015 in Bhutan and 77 patients were enrolled. Four gastric biopsies were obtained for rapid urease test, histopathology, H. pylori culture with Epsilometer test. All H. pylori-positive patients were randomized to receive either 7-day or 14-day of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily. RESULTS: Seventy-seven subjects were enrolled (54 females, 23 males, mean age = 45.4 years). Of 77 patients, 52 (67.5%) received 7-day regimen while 25 (32.5%) had 14-day regimen. Prevalence of H. pylori was 38.2%. Antibiotic resistance was 80.0% for metronidazole, 11.1% for levofloxacin and no resistance seen in amoxicillin, tetracycline and clarithromycin. Overall eradication rates of 7-day and 14-day regimens were 51.9% and 80.0%, p = 0.02. Female and age ≥40 years had significantly higher eradication rate when receiving 14-day compared to 7-day regimen (94.1% vs. 45.9%, OR = 18.82; 95% CI 2.26-157.02, p = 0.0007 and 86.7% vs. 50.0%, OR = 6.50; 95% CI 1.25-33.91, p = 0.02, respectively). CONCLUSIONS: Fourteen-day regimen might be an acceptable regimen for H. pylori eradication in limited resource area such as Bhutan. Female and age ≥40 years should receive longer duration of treatment. This 14-day regimen could at least reduce the risk of developing H. pylori-associated diseases especially peptic ulcer with complications and gastric cancer which lead to many deaths in Bhutan. West Asia Organization for Cancer Prevention 2020-04 /pmc/articles/PMC7445957/ /pubmed/32334478 http://dx.doi.org/10.31557/APJCP.2020.21.4.1109 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vilaichone, Ratha-Korn
Aumpan, Natsuda
Ratanachu-ek, Thawee
Gumnarai, Pornpen
Uchid, Tomohisa
Tshering, Lotay
Mahachai, Varocha
Yamaoka, Yoshio
Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)
title Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)
title_full Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)
title_fullStr Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)
title_full_unstemmed Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)
title_short Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)
title_sort efficacy of omeprazole, tetracycline, and 4 times daily dosing of amoxicillin in helicobacter pylori eradication in limited resource area in bhutan: a prospective randomized trial (bhutan study)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445957/
https://www.ncbi.nlm.nih.gov/pubmed/32334478
http://dx.doi.org/10.31557/APJCP.2020.21.4.1109
work_keys_str_mv AT vilaichonerathakorn efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy
AT aumpannatsuda efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy
AT ratanachuekthawee efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy
AT gumnaraipornpen efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy
AT uchidtomohisa efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy
AT tsheringlotay efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy
AT mahachaivarocha efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy
AT yamaokayoshio efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy